Neuropharmacological and pharmacokinetic properties of berberine: a review of recent research
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: This review summarizes recent research on the neuropharmacological and pharmacokinetic properties of berberine, an isoquinoline alkaloid extracted from Coptidis rhizoma. KEY FINDINGS: Berberine has multiple neuropharmacological properties, such as neuroprection, anti-neuronal apoptosis, improvement of cerebral microcirculation and anti-Alzheimer's disease, and so on. The pharmacokinetic characteristics of berberine are that it is not easily absorbed and it is not stable in the gastrointestinal tract of animals or humans. SUMMARY: Further studies need to be carried out to develop berberine as a drug for nervous system diseases, such as brain ischaemia and Alzheimer's disease, that has favorable pharmacokinetic properties.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159 · cited 1×
“There are several hypotheses to explain the underlying mechanisms of AD, including the cholinergic hypothesis, the amyloid protein (Ab)-toxicity hypothesis and the oxidative stress hypothesis.([27,28]) These hypotheses are very useful as a guide in the search for novel strategies against AD or to explain the effects o…”
Background
Cited by
The metabolism of berberine and its contribution to the pharmacological effects
Wang, K., Feng, X., Chai, L., Cao, S., & Qiu, F. (2017) · Drug Metabolism Reviews · doi:10.1080/03602532.2017.1306544 · Cited by 502
Durairajan, S. S. K., Liu, L.-F., Lu, J.-H., Chen, L.-L., Yuan, Q., Chung, S. K., Huang, L., Li, X.-S., Huang, J.-D., & Li, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.02.016 · Cited by 271
Battu, S. K., Repka, M. A., Maddineni, S., Chittiboyina, A. G., Avery, M. A., & Majumdar, S. (2010) · AAPS PharmSciTech · doi:10.1208/s12249-010-9520-y · Cited by 259
Pharmacological effects of berberine and its derivatives: a patent update
Jin, Y., Khadka, D. B., & Cho, W.-J. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1118060 · Cited by 174
Och, A., Och, M., Nowak, R., Podgórska, D., & Podgórski, R. (2022) · Molecules · doi:10.3390/molecules27041351 · Cited by 104
Anti-Cholinesterase Combination Drug Therapy as a Potential Treatment for Alzheimer’s Disease
Amat-ur-Rasool, H., Ahmed, M., Hasnain, S., & Carter, W. G. (2021) · Brain Sciences · doi:10.3390/brainsci11020184 · Cited by 43
Quasi-Irreversible Inhibition of CYP2D6 by Berberine
Kim, H. G., Lee, H. S., Jeon, J. S., Choi, Y. J., Choi, Y. J., Yoo, S.-Y., Kim, E.-Y., Lee, K., Park, I., Na, M., et al. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100916 · Cited by 21
Metadata
- Authors
- Ye, M., Fu, S., Pi, R., & He, F.
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-07-01
- Volume
- 61
- Issue
- 7
- Pages
- 831-837
- ISSN
- 0022-3573 (ISSN-L)
- OpenAlex
- W2021483454
- Cited by
- 121
- References
- 1
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.